Therefore, epigenetic therapies targeting pathways such as EZH2 could be explored, given the loss of the transcriptional repressor REST in both AMPC and NEPC, indicating a potential role for epigenetic dysregulation in these prostate cancers. This evidence concerns the gene EZH2 and prostate carcinoma.